Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||25 February 2016|
|PDF File Size:||1.17 Mb|
|ePub File Size:||6.49 Mb|
|Price:||Free* [*Free Regsitration Required]|
Emcure Pharmaceuticals withdraws proposed IPO | VCCircle
Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals. Emcure is ranked the 14th largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products, according to healthcare services information provider IMS Health India. Edited by Joby Puthuparampil Johnson. Ltd with returns of almost three times.
In AprilEmcure acquired Heritage Pharmaceuticals, a New Jersey-based generic pharmaceutical company, which provided it a commercial platform to market and sell its products. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a By Jasleen Kaur Batra. Link Intime India Private Limited is a registrar to the issue. Leave Your Comment s. This will alert our moderators to take action. This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount.
Reliance to buy majority stake in renewable energy services firm Kanoda. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus DRHP with SEBI for initial public offering that includes fresh issue of upto Rs crore and an offer for sale of upto 25,13, equity share. Emcure Pharmaceuticals withdraws proposed IPO. The company is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
For the nine months ended December 31,Emcure’s revenue from operations was Rs 1, crore with net profit at Rs Private equity major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals.
Emcure Pharmaceuticals files IPO papers with SEBI –
It is ranked as the 7th-largest pharmaceutical company in the therapeutic areas in which it operates. Emcure was the first private equity investment by a Blackstone-managed fund in India. Blackstone had invested Rs crore in Emcure through convertible shares and held These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients.
From Berlin to Washington: The IPO comprises a fresh issue of equity shares aggregating up to Rs crore and an offer for sale of up to 2, equity shares by certain existing shareholders of the company, a statement issued here said.
Promoter Satish Ramanlal Mehta holds These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients. Navy divers re-enter shaft, want water level reduced New Year eve: Thu, Dec 19 Technicals Technical Chart Visualize Screener. BSCPL is an infrastructure development company which operates in road, irrigation, real estate and hydro power projects.
Get instant notifications from Economic Times Allow Not now. The content may not be copied, broadcast, downloaded and stored in any mediumtransmitted, adapted or changed in any way whatsoever without the prior drbp permission of Mosaic Media Ventures Private Limited.
Warren Buffett has this piece of advice for youngsters and it’s not stocks. Fri, Dec 20 The issue also involves a secondary sale 2.
Of these revenues, The firm is now evaluating options for an offshore listing. Interestingly, all the firms which decided not to go ahead with public floats are backed by private equity investors. The PE firm is selling around 1. In AprilEmcure acquired Heritage Pharmaceuticals, a New Jersey-based generic pharmaceutical company, which provided it emcurw commercial platform to market drnp sell its products. Bain Capital has paid nearly Rs. Emcure Pharmaceuticals withdraws proposed IPO. Emcure Pharmaceuticals acquires Canadian company and its marketing arm Marcan.
Emcure becomes the first proposed IPO to be withdrawn after the election results and the fourth since January 1 this year.
Emcure is ranked among the top 15 pharmaceutical companies in India in terms of market share based on the domestic sales of pharmaceutical products. Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
The transaction is subject to conditions under contract and law including Foreign Investment Promotion Board approval.
Antibiotics made by Emcure Pharmaceuticals recalled in US. Deepti Chaudhary Malvika Joshi. Drag according to your convenience. Of these revenues, drph NIFTY 50 10, 2. Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products. Choose your reason below and click on the Report button.
Blackstone has exited now.